Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3082 MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom
Introduction: Literature on MEN1 associated PNETS as a unique clinico-pathological entity is evolving.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Venkataraman H
Authors: Venkataraman H, Hegde P, Purewal T, Smith S, Vicarage S,
Keywords: Pancreatic neuroendocrine tumors, Multiple endocrine neoplasia, sporadic pancreatic neuroendocrine tumors,
#3078 Gastroenteropancreatic Neuroendocrine Tumor: Experience of an Algerian Centre
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) constitute a rare and heterogeneous group of tumors and still constitute a diagnostic and therapeutic challenge.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: gastroenteropancreatic neuroendocrine tumor, centre experience, treatment, survival,
Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, Elio G,
Keywords: Functioning pancreatic neuroendocrine tumors, pancreatic surgery,
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,
Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Iyer A
Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,
Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,